Bionano Genomics, Inc. (NASDAQ:BNGO) Canaccord Genuity 43rd Annual Growth Conference August 10, 2023 11:30 AM ET Company Participants Erik Holmlin - President and Chief Executive Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Kyle Mikson Welcome to the Canaccord Genuity Global Growth Conference. I'm Kyle Mikson of Life Science Tools and Diagnostics for Canaccord. Pleased to have Bionano Genomics here. Bionano offers one of the leading platforms for optical genome mapping. With us from ...

Bionano Genomics, Inc. (NASDAQ:BNGO) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants David Holmes - IR Erik Holmlin - CEO Chris Stewart - CFO Conference Call Participants Jason McCarthy - Maxim Group Mark Massaro - BTIG Sung Ji Nam - Scotiabank Daniel Hultberg - Oppenheimer Michael Okunewitch - Maxim Group Operator Good day, and welcome to the Bionano's Second Quarter 2023 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the c ...

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) This section presents Bionano Genomics' unaudited condensed consolidated financial statements, showing a **$76.0 million** net loss for H1 2023, an accumulated deficit of **$424.8 million**, and a "going concern" warning [Condensed Consolidated Financial Statements](index=4&type=section&id=Condensed%20Consolidated%20Financial%20Statements) The financial statements show total assets decreased to **$271.4 million** by June 30, 2023, with a net loss of **$38.9 million** for Q2 2023 and **$76.0 million** for H1 2023, and **$69.1 million** cash used in operations Condensed Consolidated Balance Sheet (Unaudited) | Assets & Liabilities | June 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Total Current Assets** | $122,575,000 | $157,298,000 | | **Total Assets** | $271,381,000 | $307,502,000 | | **Total Current Liabilities** | $33,499,000 | $35,884,000 | | **Total Liabilities** | $56,625,000 | $58,104,000 | | **Total Stockholders' Equity** | $214,756,000 | $249,398,000 | Condensed Consolidated Statements of Operations (Unaudited) | Metric | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2023 | | :--- | :--- | :--- | | **Total Revenue** | $8,662,000 | $16,077,000 | | **Loss from Operations** | $(39,238,000) | $(77,083,000) | | **Net Loss** | $(38,912,000) | $(76,038,000) | | **Net Loss Per Share** | $(1.24) | $(2.46) | Condensed Consolidated Statements of Cash Flows (Unaudited, Six Months Ended) | Cash Flow Activity | June 30, 2023 | June 30, 2022 | | :--- | :--- | :--- | | **Net cash used in operating activities** | $(69,109,000) | $(60,826,000) | | **Net cash provided by investing activities** | $46,104,000 | $63,204,000 | | **Net cash provided by financing activities** | $32,743,000 | $210,000 | [Notes to Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes detail the company's basis of presentation, significant accounting policies, and a key disclosure of substantial doubt about its going concern ability due to recurring losses, also breaking down revenue by source and geography, and outlining fair value measurements including a **$24.6 million** contingent consideration liability - The company has experienced recurring net losses, negative cash flows, and an accumulated deficit of **$424.8 million** as of June 30, 2023. Management has concluded there is substantial doubt about the company's ability to continue as a going concern[37](index=37&type=chunk) - On August 4, 2023, the company effected a 1-for-10 reverse stock split. All share and per-share amounts in the financial statements have been retroactively adjusted[385](index=385&type=chunk)[393](index=393&type=chunk) Revenue by Source (Six Months Ended June 30) | Revenue Source | 2023 | 2022 | | :--- | :--- | :--- | | Instruments | $4,346,000 | $4,042,000 | | Consumables | $5,188,000 | $2,987,000 | | Software | $2,522,000 | $1,972,000 | | **Total product revenue** | **$12,056,000** | **$9,001,000** | | Service and other | $4,021,000 | $3,365,000 | | **Total revenue** | **$16,077,000** | **$12,366,000** | Revenue by Geographic Location (Six Months Ended June 30) | Region | 2023 | 2022 | | :--- | :--- | :--- | | Americas | $7,757,000 | $5,940,000 | | EMEA | $5,740,000 | $4,348,000 | | Asia Pacific | $2,580,000 | $2,078,000 | | **Total** | **$16,077,000** | **$12,366,000** | - The fair value of contingent consideration liabilities related to the BioDiscovery and Purigen acquisitions was **$24.6 million** as of June 30, 2023, measured using Level 3 inputs[86](index=86&type=chunk)[87](index=87&type=chunk)[185](index=185&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=23&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's financial performance, highlighting a **30%** year-over-year revenue increase for Q2 2023 driven by **43%** Saphyr system installed base growth, noting rising operating expenses led to a significant net loss, and emphasizing liquidity challenges with substantial doubt about going concern and a **$20 million** cost-reduction initiative [Overview and Recent Highlights](index=23&type=section&id=Overview%20and%20Recent%20Highlights) The company provides genome analysis solutions, with Q2 2023 highlights including a **43%** year-over-year increase in Saphyr installed base to **281 systems** and a **108%** increase in flowcell sales to **7,062**, while acknowledging geopolitical and macroeconomic risks - The installed base of Saphyr systems grew to **281** as of June 30, 2023, an increase of approximately **43%** from **196** as of June 30, 2022[94](index=94&type=chunk) - The company sold **7,062** flowcells in Q2 2023, a **108%** increase from **3,394** sold in Q2 2022. For the first six months of 2023, **12,288** flowcells were sold, an **86%** increase from the same period in 2022[94](index=94&type=chunk) [Results of Operations](index=25&type=section&id=Results%20of%20Operations) This section compares operating results for Q2 2023 and H1 2023 versus 2022, showing total revenue grew **30%** in Q2 2023 with gross margin improving to **27%**, but total operating expenses increased **24%** to **$41.5 million**, resulting in a wider net loss of **$38.9 million** Comparison of Results of Operations (Three Months Ended June 30) | Metric | 2023 | 2022 | Change (%) | | :--- | :--- | :--- | :--- | | **Total Revenue** | $8,662,000 | $6,670,000 | 30% | | Product Revenue | $6,609,000 | $4,795,000 | 38% | | **Total Cost of Revenue** | $6,354,000 | $5,199,000 | 22% | | **Gross Profit** | $2,308,000 | $1,471,000 | 57% | | **Gross Margin** | 27% | 22% | - | | **R&D Expenses** | $14,610,000 | $11,767,000 | 24% | | **SG&A Expenses** | $26,936,000 | $21,783,000 | 24% | | **Loss from Operations** | $(39,238,000) | $(32,079,000) | 22% | - For the six months ended June 30, 2023, product revenue increased by **34%** year-over-year, driven by increased demand for Saphyr OGM solutions and a **43%** increase in the instrument installed base[156](index=156&type=chunk) - SG&A expenses for Q2 2023 increased by **$5.2 million** (**24%**) YoY, primarily due to higher compensation, amortization of intangibles from the Purigen acquisition, increased professional services, and a **$1.4 million** increase in the fair value of contingent consideration liabilities[173](index=173&type=chunk) [Liquidity and Capital Resources](index=30&type=section&id=Liquidity%20and%20Capital%20Resources) The company has a history of net losses and negative cash flows, with an accumulated deficit of **$424.8 million**, leading to substantial doubt about its going concern ability as current cash and securities are insufficient for the next 12 months, prompting financing evaluations and a cost-saving plan, having raised **$33.5 million** via ATM in H1 2023 - The company has determined there is substantial doubt about its ability to continue as a going concern, as its available cash balance is not expected to be sufficient for the next twelve months[122](index=122&type=chunk)[203](index=203&type=chunk) - As of June 30, 2023, the company had approximately **$14.9 million** in cash and cash equivalents and **$62.2 million** in available-for-sale securities[202](index=202&type=chunk) - In May 2023, the company announced a cost-reduction initiative to reduce cash expenditures by approximately **$20.0 million** over the next four to five quarters[203](index=203&type=chunk) - During the six months ended June 30, 2023, the company sold approximately **3.5 million** shares of common stock under its Cowen ATM facility, receiving gross proceeds of approximately **$33.5 million**[184](index=184&type=chunk)[206](index=206&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=32&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company is exposed to market risks from interest rates, foreign currency exchange, and inflation, with a **100 basis point** interest rate change estimated to have a **$0.1 million** impact, and foreign currency risk from international operations not considered material, while inflation has not yet materially affected operations - A hypothetical **100 basis point** change in interest rates would have an approximate **$0.1 million** impact on the company's investments[190](index=190&type=chunk) - Foreign currency exposures are primarily concentrated in the British Pound, Chinese Renminbi, Euro, and Canadian dollar. A hypothetical **10%** change in foreign exchange rates is not expected to have a material impact[191](index=191&type=chunk) - The company does not believe that inflation has had a material effect on its business or financial condition to date, but acknowledges risks if inflationary pressures increase[192](index=192&type=chunk) [Item 4. Controls and Procedures](index=34&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded the company's disclosure controls and procedures were effective as of June 30, 2023, while actively integrating the internal controls of Purigen Biosystems, Inc., acquired in November 2022 - Management concluded that the company's disclosure controls and procedures were effective as of June 30, 2023[214](index=214&type=chunk) - The company is in the process of integrating the internal controls of Purigen Biosystems, Inc., acquired in November 2022[238](index=238&type=chunk) PART II. OTHER INFORMATION [Item 1. Legal Proceedings](index=35&type=section&id=Item%201.%20Legal%20Proceedings) The company reports that it is not currently a defendant in any material claims or legal actions - The company is not currently a defendant in any claims or legal actions that are considered material[59](index=59&type=chunk)[239](index=239&type=chunk) [Item 1A. Risk Factors](index=35&type=section&id=Item%201A.%20Risk%20Factors) This section details numerous significant risks, including recurring losses and going concern doubt, dependence on market acceptance, intense competition, reliance on single-source manufacturers, significant FDA regulatory risks for "Research Use Only" products, acquisition integration challenges, intellectual property protection, and high stock price volatility - The company's recurring losses, negative cash flows, and significant accumulated deficit have raised substantial doubt about its ability to continue as a going concern[122](index=122&type=chunk)[242](index=242&type=chunk) - The company relies on a single contract manufacturer for its OGM-based instruments and another single contract manufacturer for its chip consumables, creating significant supply chain risk[261](index=261&type=chunk)[286](index=286&type=chunk) - The company's products are currently for "Research Use Only" (RUO). If the FDA were to determine these products are medical devices or if the company seeks diagnostic use, it would face an expensive, time-consuming, and uncertain regulatory clearance process[260](index=260&type=chunk)[317](index=317&type=chunk) - The company's stock price has been and may continue to be highly volatile. A reverse stock split was implemented in August 2023, but it may not achieve its intended results, such as maintaining Nasdaq listing compliance[141](index=141&type=chunk)[143](index=143&type=chunk) - The life sciences research and diagnostic markets are highly competitive, and the company faces competition from established companies with greater financial resources, brand recognition, and broader product lines[271](index=271&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=77&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section discloses the company's purchases of its own equity securities, specifically the repurchase of one share of Series A Preferred Stock for **$100.00** in Q2 2023, which was issued to facilitate a stockholder vote and automatically redeemed Issuer Purchases of Equity Securities (Q2 2023) | Period | Total Number of Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | April 1 - April 30, 2023 | - | - | | May 1 - May 31, 2023 | - | - | | June 1 - June 30, 2023 | 1 | $100.00 | | **Total** | **1** | **$100.00** | - The single share repurchased was a share of Series A Preferred Stock, which was issued on April 13, 2023, and automatically redeemed on June 14, 2023, following the Annual Meeting of Stockholders[79](index=79&type=chunk)[97](index=97&type=chunk) [Item 3. Defaults Upon Senior Securities](index=77&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports that there were no defaults upon senior securities during the period - None[98](index=98&type=chunk) [Item 4. Mine Safety Disclosures](index=77&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) The company reports that this item is not applicable - Not applicable[131](index=131&type=chunk) [Item 5. Other Information](index=79&type=section&id=Item%205.%20Other%20Information) The company reports no other information for this item - None[131](index=131&type=chunk) [Item 6. Exhibits](index=80&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the 10-Q report, including corporate documents like the Amended and Restated Certificate of Incorporation, bylaws, and warrant forms, along with certifications from the Principal Executive Officer and Principal Financial Officer as required by Sarbanes-Oxley Act, and Inline XBRL data files - The report includes certifications from the Principal Executive Officer and Principal Financial Officer pursuant to SEC rules and the Sarbanes-Oxley Act of 2002[133](index=133&type=chunk) - Key corporate documents filed as exhibits include the Amended and Restated Certificate of Incorporation, bylaws, and various forms of warrants[133](index=133&type=chunk)

Financial Data and Key Metrics Changes - Revenue for Q1 2023 was $7.4 million, representing a 30% year-over-year increase, marking the largest increase for any Q1 ever and the 10th consecutive quarter of year-over-year revenue growth [20][68] - GAAP operating expense for Q1 2023 was $39.9 million, compared to $30.8 million in Q1 2022, while non-GAAP operating expense was $33.6 million compared to $24.2 million in the same period [27][69] - GAAP gross margin for Q1 was 28%, and non-GAAP gross margin was 30%, nearly double the 15% gross margin from Q1 2022 [44] Business Line Data and Key Metrics Changes - The company sold 5,226 flow cells in Q1 2023, a 62% year-over-year increase from 3,225 flow cells sold in Q1 2022 [21] - The installed base of Saphyr systems grew by 19 systems to 259, representing a 47% growth over the installed base of 176 at the end of Q1 2022 [38] Market Data and Key Metrics Changes - The cumulative total of human-focused clinical research publications describing optical genome mapping grew from 23 at the end of 2020 to 108 at the end of 2022, with 16 new publications in Q1 2023 [22][23] Company Strategy and Development Direction - The company is focused on advancing clinical studies to support reimbursement for optical genome mapping (OGM) and seeking FDA clearance for clinical use [30][47] - A strategic review led to a cost reduction initiative aimed at reducing cash expenditures by approximately $20 million over the next four to five quarters [24][41] - The Elevate strategy prioritizes expanding leadership in cytogenetics and driving acceptance of OGM while investing in R&D and strategic partnerships [41] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging state of capital markets but emphasized a focus on executing the strategic plan to drive long-term shareholder value [68] - The company plans to hold preliminary discussions with the FDA regarding the new mapping system by the end of the year [31] Other Important Information - The company raised $14.8 million through its ATM facility, selling 9.5 million shares at an average price of $1.60 [4] - Cash, cash equivalents, and available-for-sale securities as of March 31, 2023, were $95.8 million [45] Q&A Session Summary Question: What are the next steps regarding the hematological malignancy publication? - Management indicated that additional studies may be needed to start conversations with guideline bodies for OGM [7] Question: What is the company's strategy regarding CPT codes? - Management emphasized the importance of obtaining a Category 1 CPT code for OGM and the need to present data to payers, starting with Medicare [54][56] Question: Can you elaborate on the cost reduction measures? - Management clarified that the cost reductions are targeted across operating expenses, cost of goods sold, and inventory reduction, with some reductions being recurring [91][96] Question: What are the main bottlenecks for OGM end users? - Management identified data analysis as a significant bottleneck, particularly due to the guideline-driven nature of cancer research [88][89]

A summary of the Company's stock option activity during the three months ended March 31, 2023 was as follows: | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------|-------|-------------|-------|-------------------------------------------|-------|--------------------------------|--------------------------------------------|-------|---------------------------| | | | | | Shares of Stock under Stock Options | | WeightedAverage Exercise Price | WeightedAverage Remaining Cont ...

Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Chris Stewart - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Sung Ji Nam - Scotiabank Michael Okunewitch - Maxim Group Mark Massaro - BTIG Operator Good day and welcome to the Bionano Fourth Quarter and Full Year 2022 Earnings Conference Call. [Operator Instructions] Please be advised that ...

• sales of our securities by us or our stockholders in the future; • trading volume of our securities; • changes in accounting practices; • ineffectiveness of our internal controls; • data breaches of our company, providers, vendors or customers; • regulatory or legal developments in the United States and other countries; • disputes or other developments relating to proprietary rights, including our ability to adequately protect our proprietary rights in our technologies; • significant lawsuits, including p ...

Bionano Genomics, Inc. (NASDAQ:BNGO) Cowen 43rd Annual Healthcare Conference March 6, 2023 1:30 PM ET Company Participants Erik Holmlin - Chief Executive Officer Conference Call Participants Tom Stevens - Life Science Tools & Diagnostic Team here at Cowen Tom Stevens All right, so should we get started?. So I’m Tom Stevens, Life Science Tools & Diagnostic Team here at Cowen. We have Erik Holmlin, take us through with his presentation and have agreed to name it, take it away. Erik Holmlin Great. Thank you ve ...

Bionano Genomics, Inc. (NASDAQ:BNGO) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Christopher Stewart - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Good day, and welcome to the Bionano Genomics Third Quarter 2022 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Amy Conrad from ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file numb ...